Xofluza is now approved in the EU for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza in children aged one year and above, and in adolescents and adultsXofluza is
Xofluza, a flu antiviral drug developed by Roche and Shionogi, is now approved in Europe for children age 1 and older. The European Commission decision expands the patient population for the drug, which was previously approved for treating adolescents and adults.
According to the Alabama Department of Public Health, the state has seen the highest volume of flu-like activity for this time of year since the 2009 H1N1 pandemic.
According to the Alabama Department of Public Health, the state has seen the highest volume of flu-like activity for this time of year since the 2009 H1N1 pandemic.
SOUTH SAN FRANCISCO (dpa-AFX) - The FDA has approved the expanded use of Roche Holding AG's (RHHBY) single-dose flu drug Xofluza to treat acute uncomplicated influenza in otherwise healthy children